Work

AVITHRAPID - Standard Operating Procedure - Antiviral activity evaluation by CPE – Virucidal compounds

Year: 2026

Type: article

Abstract: When evaluating the antiviral effect of a compound, assessing cellular toxicity in the target cell line is an essential prerequisite (see dedicated SOP). The highest dose allowing > 90 % cell viability is the first tested dose in antiviral assay. SARS-CoV-2, WNV and CHIKV infections on Vero E6 cell line causes a cytopathic effect (CPE) that can be used as a simple, low-cost first-line method for evaluating the antiviral efficacy of compounds.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.20408027

Author: Bull-Maurer, Anne

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: European Commission

Award: Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases